2026 Q2 Portfolio Activity
In 2026 Q2, Saturn V Capital Management LP maintained a portfolio of 24 distinct positions. The most significant new addition was TREVI THERAPEUTICS INC, now representing 2.81% of the total fund value. They heavily accumulated shares in CANDEL THERAPEUTICS INC, increasing the position by 14.1%. Conversely, Saturn V Capital Management LP completely exited their position in COGENT BIOSCIENCES INC.
Position History
hover any row below to update
Loading…
Total Positions
24
Quarter
2026 Q2
Top Holding
AMLX (11.9%)
Top 10 Concentration
75.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-24 of 24
Saturn V Capital Management LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 11.91% | 10.95% |
#1
1
Prev: #2
|
8.0 |
—
|
274,216 | 6.3% |
P
S
|
4,624,101 | $83,048,854 |
$10.48
+206.1%
|
2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
ALMS
ALUMIS INC
|
Healthcare | 11.76% | 12.77% |
#2
1
Prev: #1
|
6.0 |
—
|
-286,632 | -9.0% |
P
S
|
2,915,443 | $82,040,566 |
$10.01
-1.1%
|
2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
ABVX
ABIVAX SA
|
Healthcare | 9.91% | 10.94% |
#3
Prev: #3
|
5.5 |
—
|
-23,831 | -4.4% |
P
S
|
518,865 | $69,143,950 |
$27.68
+328.6%
|
2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
PCVX
VAXCYTE INC
|
Healthcare | 7.11% | 8.68% |
#4
Prev: #4
|
3.8 |
—
|
28,382 | 3.4% |
P
S
|
852,914 | $49,579,891 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMMX
IMMIX BIOPHARMA...
|
Healthcare | 6.89% | 6.09% |
#5
1
Prev: #6
|
5.8 |
—
|
964,844 | 26.1% |
P
S
|
4,658,429 | $48,028,403 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 6.52% | 6.15% |
#6
1
Prev: #5
|
4.6 |
—
|
112,720 | 9.4% |
P
S
|
1,314,122 | $45,442,339 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 5.56% | 5.58% |
#7
1
Prev: #8
|
2.7 |
—
|
-2,023 | -1.2% |
P
S
|
160,938 | $38,781,230 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CELC
CELCUITY INC
|
Healthcare | 5.55% | 5.83% |
#8
1
Prev: #7
|
4.7 |
—
|
88,414 | 31.4% |
P
S
|
370,318 | $38,742,669 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 5.50% | 5.21% |
#9
Prev: #9
|
4.2 |
—
|
74,804 | 16.6% |
P
S
|
524,730 | $38,378,752 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CADL
CANDEL THERAPEU...
|
Healthcare | 4.88% | 2.57% |
#10
5
Prev: #15
|
4.0 |
—
|
407,098 | 14.1% |
P
S
|
3,303,686 | $34,027,966 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 4.67% | 4.83% |
#11
1
Prev: #10
|
3.9 |
—
|
516,697 | 8.0% |
P
S
|
6,973,343 | $32,565,512 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 4.14% | 3.43% |
#12
Prev: #12
|
2.2 |
—
|
-33,650 | -9.7% |
P
S
|
311,976 | $28,885,858 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 3.37% | 3.17% |
#13
Prev: #13
|
3.3 |
—
|
90,884 | 9.4% |
P
S
|
1,057,493 | $23,486,920 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 2.81% | — |
#14
Prev: #—
|
4.6 |
—
|
1,052,043 | — |
NEW
|
1,052,043 | $19,620,602 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 1.78% | 0.80% |
#15
4
Prev: #19
|
3.7 |
—
|
1,361,159 | 184.0% |
P
S
|
2,101,119 | $12,396,602 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SGMT
SAGIMET BIOSCIE...
|
Healthcare | 1.64% | — |
#16
Prev: #—
|
4.2 |
—
|
1,479,918 | — |
NEW
|
1,479,918 | $11,439,766 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OCS
OCULIS HOLDING ...
|
Healthcare | 1.36% | 2.49% |
#17
1
Prev: #16
|
3.0 |
—
|
168,119 | 32.5% |
P
S
|
684,880 | $9,499,286 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.13% | 1.18% |
#18
Prev: #18
|
1.0 |
—
|
5,611 | 0.1% |
P
S
|
3,869,056 | $7,854,184 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VIR
VIR BIOTECHNOLO...
|
Healthcare | 1.13% | — |
#19
Prev: #—
|
4.0 |
—
|
770,643 | — |
NEW
|
770,643 | $7,852,852 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IVVD
INVIVYD INC
|
Healthcare | 1.05% | 2.58% |
#20
6
Prev: #14
|
0.4 |
—
|
-2,556,796 | -23.4% |
P
S
|
8,392,288 | $7,321,432 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 0.69% | 0.36% |
#21
1
Prev: #20
|
3.3 |
—
|
93,830 | 105.4% |
P
S
|
182,829 | $4,824,857 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
SATELLOS BIOSCI...
|
|
Unknown | 0.39% | 0.36% |
#22
1
Prev: #21
|
1.2 |
—
|
no change | no change |
P
S
|
350,000 | $2,721,250 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 0.26% | 1.68% |
#23
6
Prev: #17
|
0.1 |
—
|
-3,503,606 | -84.1% |
P
S
|
663,060 | $1,783,631 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 0.00% | 4.37% |
Sold All 😨
(Was: #11) |
0.0 |
—
|
-626,635 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-24 of 24 holdings